Semaglutide News and Research

Latest Semaglutide News and Research

New diabetes drugs linked to increased risk of pancreatitis and pancreatic cancer

Two newer drugs used to treat Type 2 diabetes could be linked to a significantly increased risk of developing pancreatitis and pancreatic cancer, and one could also be linked to an increased risk of thyroid cancer, according to a new UCLA study.

17 Sep 2011

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

ConjuChem, LLC, a biotechnology company dedicated to the discovery of novel therapeutics, today announced it has initiated patient enrollment for its Phase 2 clinical trial of its proprietary GLP-1 receptor agonist drug, CJC-1134-PC, in patients with Type 2 diabetes mellitus who are receiving metformin monotherapy.

15 Sep 2011

Lexicon's LX4211 clinical data presented at EASD annual meeting

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company is presenting clinical data this week at the European Association for the Study of Diabetes (EASD) annual meeting in Lisbon, Portugal.

14 Sep 2011

Sanofi's Lyxumia achieves primary efficacy endpoint in study of patients uncontrolled on metformin

Sanofi announced today that Lyxumia (lixisenatide), a once-daily GLP-1 receptor agonist under development for type 2 diabetes, achieved its primary efficacy endpoint of significant HbA1c reduction vs. placebo in patients uncontrolled on metformin.

12 Sep 2011

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.

9 Aug 2011

Femta files IND with FDA for FM101 monoclonal antibody against RA

Femta Pharmaceuticals announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to initiate a clinical development program for FM101, a high-affinity, humanized monoclonal antibody against Interleukin-6 (IL-6), in patients with rheumatoid arthritis (RA).

1 Aug 2011

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the companies have submitted their reply to a complete response letter issued in October 2010 by the U.S. Food and Drug Administration (FDA) regarding BYDUREON™ (exenatide extended-release for injectable suspension), an investigational medication for type 2 diabetes.

28 Jul 2011

Roux-en-Y gastric bypass appears to reduce dietary fat intake

Roux-en-Y gastric bypass, the most common type of bariatric surgery in the United States, is currently considered the most effective therapy for morbid obesity.

28 Jul 2011

Roux-en-Y gastric bypass surgery can lead to effective weight loss

Imperial College London. The findings, published in the American Journal of Physiology—Regulatory, Integrative, and Comparative Physiology, suggest a new mechanism by which some types of bariatric surgery lead to long-term weight loss.

28 Jul 2011

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Takeda Pharmaceutical Company Limited announced today that Takeda Global Research & Development Center, Inc., resubmitted two New Drug Applications to the United States Food and Drug Administration for alogliptin and the fixed-dose combination therapy alogliptin/pioglitazone, which combines alogliptin with pioglitazone in a single tablet.

26 Jul 2011

Isis commences ISIS-PTP1BRx Phase 1 study in type 2 diabetes

Isis Pharmaceuticals, Inc. announced today that it has initiated a Phase 1 clinical study for ISIS-PTP1BRx, an antisense drug for the treatment of type 2 diabetes targeting protein tyrosine phosphatase-1B, PTP-1B.

21 Jul 2011

Two instruments of Thermo Fisher Scientific win 2011 R&D 100 Award

Thermo Fisher Scientific, the world leader in serving science, today announced that two of its instruments are 2011 R&D 100 Award winners: the Thermo Scientific Evolution 200 series UV-Vis spectrophotometer and the Thermo Scientific Dionex ICS-5000 capillary ion chromatography system.

From Thermo Fisher Scientific Inc. 20 Jul 2011

OncoVista commences OVI-117 additional safety study in a second animal species

OncoVista Innovative Therapies, Inc. reported that it has initiated an additional safety study of OVI-117 in a 2nd animal species.

14 Jul 2011

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

Sanofi announced today data from four studies of its once-daily GLP-1 receptor agonist Lyxumia that is in Phase III clinical development, including data that demonstrates positive results in type 2 diabetes patients not at goal on oral therapies or with basal insulin.

27 Jun 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

In a new post-hoc analysis based on the American Association of Clinical Endocrinologists (AACE/ACE) diabetes algorithm presented at the American Diabetes Association (ADA) 71st Annual Scientific Sessions, significantly more patients with type 2 diabetes treated with JANUMET-tablets achieved blood sugar goals after 18 weeks compared to metformin as initial therapy.

27 Jun 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Eli Lilly and Company, together with Amylin Pharmaceuticals, Inc. and Alkermes, Inc., announced today that the European Commission has granted marketing authorization to BYDUREON.

21 Jun 2011

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

Today, Zealand Pharma, a Copenhagen based biopharmaceutical company, and Boehringer Ingelheim, one of the world's leading pharmaceutical companies, jointly announced an exclusive global licence and collaboration agreement for dual-acting glucagon and GLP-1 receptor agonists for the treatment of patients with Type-2 diabetes and patients with obesity.

16 Jun 2011

CLC bio, AROS partner to provide 'Total Genomic Solutions'

Today, CLC bio announced its collaboration with one of the premier European service providers, GLP and GCP certified AROS Applied Biotechnology who specialize in Total Genomic Solutions, covering all steps from extraction, sample banking, and analysis, to advanced bioinformatics using CLC bio's enterprise platform.

8 Jun 2011

Unigene to present proprietary recombinant production, oral peptide drug delivery technology at TIDES Summit

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the Company will be presenting a poster and an oral presentation on its propriety recombinant production and oral peptide drug delivery technology during the upcoming 2011 TIDES: Oligonucleotide and Peptide Research, Technology and Product Development Summit being held at the Hynes Convention Center and Sheraton Boston Hotel in Boston, MA from May 22 - 25, 2011.

18 May 2011

AOBO's ZD Pill and CWJ Tablet receive Chinese approval for sales in Hong Kong

American Oriental Bioengineering, Inc., a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products, today announced that the Company's Zhibai Dihuang Pill and Ciwujia Tablet have been approved for sale as traditional Chinese medicine in Hong Kong by Chinese Medicine Council of Hong Kong.

10 May 2011

Semaglutide News and Research

Latest Semaglutide News and Research

New diabetes drugs linked to increased risk of pancreatitis and pancreatic cancer

Enrollment commences in ConjuChem's CJC-1134-PC Phase 2 trial for Type 2 diabetes

Lexicon's LX4211 clinical data presented at EASD annual meeting

Sanofi's Lyxumia achieves primary efficacy endpoint in study of patients uncontrolled on metformin

Lexicon's second quarter revenues decrease 55% to $0.6 million

Femta files IND with FDA for FM101 monoclonal antibody against RA

Amylin, Lilly and Alkermes submit reply to FDA complete response letter for BYDUREON

Roux-en-Y gastric bypass appears to reduce dietary fat intake

Roux-en-Y gastric bypass surgery can lead to effective weight loss

Takeda resubmits alogliptin and fixed-dose combination therapy NDA to FDA

Isis commences ISIS-PTP1BRx Phase 1 study in type 2 diabetes

Two instruments of Thermo Fisher Scientific win 2011 R&D 100 Award

OncoVista commences OVI-117 additional safety study in a second animal species

Positive data from Lyxumia study on type 2 diabetes presented at ADA 2011

New data from JANUMET clinical study on type 2 diabetes presented at ADA 2011

EC grants marketing authorization to BYDUREON for treatment of type 2 diabetes

Boehringer Ingelheim, Zealand Pharma partner to develop Type-2 diabetes and obesity agonists

CLC bio, AROS partner to provide 'Total Genomic Solutions'

Unigene to present proprietary recombinant production, oral peptide drug delivery technology at TIDES Summit

AOBO's ZD Pill and CWJ Tablet receive Chinese approval for sales in Hong Kong

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Semaglutide News and Research

Latest Semaglutide News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in